نظام مواقع التدريسيين

Efficacy of biological agents in stricturing Crohn’s disease: a retrospective cohort study

الباحث الأول: Mahmoud Alchlaihawi

الباحثين الآخرين: Sriharan Selvaratnam, Sudarshan Paramsothy, Rupert Leong

المجلة: INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

تاريخ النشر: None

مختصر البحث:

ABSTRACT Background/Aim: Despite the effectiveness of Endoscopic balloon dilatation (EBD) in treating intestinal stricture in Crohn’s disease, there is still a high recurrence rate which leads to high rates of re-dilatation and sometimes leads to f…

عرض المزيد عرض البحث

Serum Levels of Copper in Patients with Peptic Ulcer Disease and H.pylori Infections in Najaf Governorate

الباحث الأول: ZAHRAA HAMZAH ABDULZAHRA

الباحثين الآخرين: ALI NAJI A. ALNAJEM, MAHMOUD AZIZA M. ALCHLAIHAWI AND MOHAUMAN MOHAMMAD M. AL-RUFAIE*

المجلة: Annals of Agri-Bio Research

تاريخ النشر: None

مختصر البحث:

ABSTRACT A portion from the crucial function of micronutrients such as copper in the body enzymes roles, it appears that altering in these biomarkers in the serum levels may take a function in the peptic ulcer pathogenesis. The goal of this study…

عرض المزيد عرض البحث

Evaluation of serum levels of zinc in the cases of peptic ulcers in Najaf governorate

الباحث الأول: Zahraa Hamzah Abdulzahra

الباحثين الآخرين: Mohauman Mohammad M. AL-Rufaiea, Mahmoud Azeez M. Alchlaihawib, Suhad Rashed Majeed

المجلة: Iranian Journal of Organic Chemistry

تاريخ النشر: None

مختصر البحث:

Abstract: The peptic ulcer pathogenesis is multifactorial as well as increases from imponderables between attacker agents as well as protective. This paper pursued toestimate thepotential protective function of the serum zinc concentration in patien…

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

الباحث الأول: Webber Chan

الباحثين الآخرين: G COLLINS, E LEE, A MAHMOUD R LEONG

المجلة: Journal of gastroenterology and hepatology

تاريخ النشر: None

مختصر البحث:

Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intra… Background: Infliximab (IFX) and vedolizumab (VDZ) are monoclonal antibodies targeting tumor necrosis factor-α and α4β7 integrin, respectively, and are indicated in the treatment of inflammatory bowel disease (IBD). Both are administered by intravenous infusion and may be associated with different types of infusion reactions. Aims: To compare the incidence of infusion reactions in adult patients with IBD receiving IFX and VDZ treatment and to identify when these infusion reactions happened. Methods: We performed a retrospective review of all IFX and VDZ infusions performed at Concord Repatriation General Hospital and Macquarie University Hospital, Sydney, from January 2012 through March 2017. Fisher exact test and receiver operating characteristics (ROC) curve analysis were used. Results: A total of 157 consecutive patients who received 1921 IFX infusions and 61 patients who received 509 VDZ infusions were evaluated. All patients received intravenous hydrocortisone before IFX and VDZ infusion. Most patients were on concurrent immunomodulators (azathioprine or methotrexate). The overall incidence of infusion reactions to IFX was 1.3% (25/1921 infusions), affecting 14.6% of patients (23/157); and the overall incidence of infusion reactions to VDZ was 0.2% (1/509), affecting 1.6% (1/61). Mild-to-moderate and severe acute reactions occurred in 1.2% (23/1921) and 0.1% (2/1921) of IFX infusions, respectively. One case of mild-to-moderate reaction happened in VDZ infusion, but no severe reactions were observed. Compared with VDZ, IFX was associated with more mild-to-moderate infusion reactions (such as rash, arthralgia, tachycardia, and diaphoresis) (P = 0.0425 per infusion, Table 1), whereas the difference for severe reaction (such as significant hypotension, and severe dyspnea) was not statistically significant. Based on ROC curve analysis (Figure 1), the optimal number of IFX infusions after which infusion reactions were less likely to happen was eight (P < 0.01) and that for VDZ was not statistically significant. Conclusion: IFX is associated with more mild-to-moderate infusion reactions compared withVDZ, suggesting that IFX is associated with more immunogenicity.

عرض المزيد عرض البحث

Procalcitonin, Calcium, and Magnesium in Patients with Febrile Seizure during One-Hour Attack

الباحث الأول: Hussein Kadhem Al-Hakeim

الباحثين الآخرين: Zainab Muhammed Al-Hillawi and Mahmood Aziz Al-Kindi

المجلة: British Journal of Medicine and Medical Research

تاريخ النشر: None

مختصر البحث:

Abstact Aims: Procalcitonin (PCT) is a marker used as an indicator of severe bacterial infection, which causes febrile seizure (FS). In this study, the level of PCT in patients with FS during the first hour of attack was investigated. Furthermore…

عرض المزيد عرض البحث

Correlation of Hepcidin Level with Insulin Resistance and Endocrine Glands Function in Major Thalassemia

الباحث الأول: Hussein K. Al-Hakeim

الباحثين الآخرين: Manal M. Al-Khakani Mahmood A. Al-Kindi

المجلة: Adv Clin Exp Med

تاريخ النشر: None

مختصر البحث:

Abstract Aims: Procalcitonin (PCT) is a marker used as an indicator of severe bacterial infection, which causes febrile seizure (FS). In this study, the level of PCT in patients with FS during the first hour of attack was investigated. Furthermor…

عرض المزيد عرض البحث

محمود عزيز محمد الكندي

محمود عزيز محمد الكندي

الملف الشخصي

الاهتمامات البحثية

البحوث المنشورة

Efficacy of biological agents in stricturing Crohn’s disease: a retrospective cohort study

Serum Levels of Copper in Patients with Peptic Ulcer Disease and H.pylori Infections in Najaf Governorate

Evaluation of serum levels of zinc in the cases of peptic ulcers in Najaf governorate

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Comparison of infusion reactions to infliximab and vedolizumab: A retrospective analysis

Procalcitonin, Calcium, and Magnesium in Patients with Febrile Seizure during One-Hour Attack

Correlation of Hepcidin Level with Insulin Resistance and Endocrine Glands Function in Major Thalassemia

المحاضرات

Chronic liver disease GIT block

Approach to acute and chronic diarrhea GIT block

Malabsoption GIT block

Inflammatory bowel disease GIT Module